Home/Pipeline/Disitamab Vedotin (RC48)

Disitamab Vedotin (RC48)

HER2+ Gastric Cancer

ApprovedMarketed

Key Facts

Indication

HER2+ Gastric Cancer

Phase

Approved

Status

Marketed

Company

A leading Chinese biotech developing and commercializing innovative biologics and ADCs for autoimmune diseases, oncology, and ophthalmology.

A leading Chinese biotech developing and commercializing innovative biologics and ADCs for autoimmune diseases, oncology, and ophthalmology.

A leading Chinese biotech developing and commercializing innovative biologics and ADCs for autoimmune diseases, oncology, and ophthalmology.

A leading Chinese biotech developing and commercializing innovative biologics and ADCs for autoimmune diseases, oncology, and ophthalmology.